Research Projects & Grants

For Profit Organization

  • An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis, Role: Investigator, Arena Pharmaceuticals, Inc., (07/2024 - 07/2025) Status: Approved
  • A multicentre, long-term safety, efficacy, and pharmacokinetics study of lubiprostone in paediatric subjects aged > = 6 years to less than 18 years with functional constipation, Role: PI, Sucampo Pharmaceuticals, Inc., (01/2017 - 01/2018) Status: Completed
  • A multicentre, randomized, placebo-controlled,double-blind study of the efficacy, safety, and pharmacokinetics of lubiprostone in paediatric subjects ages >/= 6 years to < 18 years with functional constipation., Role: PI, Sucampo Pharmaceuticals, Inc., (04/2016 - 04/2017) Status: Completed
  • Procter & Gamble pharmaceuticals - 2007017 (CAMP II): A randomized, double-blind, parallel-group study to assess the safety and efficacy of Asacol® (1.2 to 4.8g/day) administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with mildly-to-moderately active ulcerative, Role: PI, Procter & Gamble Company, (03/2011 - 03/2012) Status: Completed
  • CAMP III - A randomized, double-blind, parallel-group study to assess the safety and efficacy of Asacol® (1.2 to 4.8g/day) 400 mg delayed-release tablets given twice a day for 26 weeks to children and adolescents for the maintenaince of remission of ulcerative colitis, Role: PI, Procter & Gamble Company, (09/2010 - 09/2011) Status: Completed
  • Wyeth - 3001B3-335-WW - A multicenter, open-label, safety study of 2 doses of pantoprazole sodium enteric-coated spheroid suspension in infants less than 12 months with presumed GERD, Role: PI, Wyeth Pharmaceuticals, Inc., (02/2008 - 02/2009) Status: Completed
  • A multicenter, open-label pharmacokinetic, pharmacodynamic, clinical symptoms, and safety study of pantoprazole delayed-released granules administered as a suspension in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease protocol No.3001B3-331-WW, Role: PI, Wyeth Pharmaceuticals, Inc., (05/2007 - 05/2008) Status: Completed
  • Psychometric validation of the pediatric gastroesophageal reflux disease (GERD) symptom and quality of life questionnaire (PGSQ), Role: Investigator, TAP Pharmaceuticals, Inc,, (04/2007 - 04/2008) Status: Completed
  • Lansoprazole study C03-042: A Phase I, single-and repeated-dose, randomized, open-label, multicenter study to evaluate the pharmacokinetics, pharmacodynamics and safety of lansoprazole in neonates with clinically-evident gastroesophageal reflux disease, Role: PI, TAP Pharmaceuticals, Inc,, (03/2005 - 03/2006) Status: Completed
  • Lansoprazole study C03-043: A Phase I, single- and repeated-dose, randomized, open-label, multicenter study to evaluate the pharmacokinetics, pharmacodynamics and safety of lansoprazole in infants with clinically-evident gastroesophageal reflux disease, Role: PI, TAP Pharmaceuticals, Inc,, (03/2005 - 03/2006) Status: Completed

Internal

  • Comparison of altered respiratory events (ARE) detection by transcutaneous respiratory rate monitoring (TCM), capnography and pulse-oximetry in pediatric patients undergoing esophagogastroduodenoscopy and colonoscopy under procedure related sedation, Role: Investigator, LLU Dept. of Pediatrics, (05/2015 - 05/2016) Status: Completed
  • Chronic intestinal pseudo-obstruction in the pediatric population, Role: Investigator, LLU Dept. of Pediatrics, (11/2005 - 11/2006) Status: Completed
  • Electrogastrography to Measure Gastric Myoelectric Activity in Healthy Term and Preterm Infants, Role: Investigator, LLU GI Research Fund, (02/1995 - 02/1996) Status: Completed

Non-Profit Organization

  • A long-term prospective observational safety study of the incidence of and risk factors for fibrosing colonopathy in US patients with cystic fibrosis treated with pancreatic enzyme replacement therapy: A harmonized protocol across sponsors, Role: Investigator, Cystic Fibrosis Foundation, (05/2017 - 05/2018) Status: Completed